Literature DB >> 10888319

Antifungal rapamycin analogues with reduced immunosuppressive activity.

D A Dickman1, H Ding, Q Li, A M Nilius, D J Balli, S J Ballaron, J M Trevillyan, M L Smith, L S Seif, K Kim, A Sarthy, R C Goldman, J J Plattner, Y L Bennani.   

Abstract

Several 1,2,3,4-tetrahydro- and 7-N-hydroxycarbamate derivatives of the natural product rapamycin were prepared and assayed for their immunosuppressive and antifungal profiles. Substitutions at the 7-position indicate the possibility of a differentiated immunosuppressive to antifungal profile, whereas 40-position variants of the tetrahydro-analogues did not show similar differentiated activity.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10888319     DOI： 10.1016/s0960-894x(00)00184-0

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  5 in total

1.  Rational design of a ligand-controlled protein conformational switch.

Authors:  Onur Dagliyan; David Shirvanyants; Andrei V Karginov; Feng Ding; Lanette Fee; Srinivas N Chandrasekaran; Christina M Freisinger; Gromoslaw A Smolen; Anna Huttenlocher; Klaus M Hahn; Nikolay V Dokholyan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

2.  Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.

Authors:  M C Cruz; A L Goldstein; J Blankenship; M Del Poeta; J R Perfect; J H McCusker; Y L Bennani; M E Cardenas; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Authors:  William J Steinbach; Wiley A Schell; Jill R Blankenship; Chiatogu Onyewu; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  A Curvilinear-Path Umbrella Sampling Approach to Characterizing the Interactions Between Rapamycin and Three FKBP12 Variants.

Authors:  Dhananjay C Joshi; Charlie Gosse; Shu-Yu Huang; Jung-Hsin Lin
Journal:  Front Mol Biosci       Date:  2022-07-08

5.  Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.

Authors:  Ronak Vakil; Kayla Knilans; David Andes; Glen S Kwon
Journal:  Pharm Res       Date:  2008-04-16       Impact factor: 4.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.